Calithera Biosciences, a South San Francisco, CA-based biotechnology company focused on the development of novel cancer therapeutics, completed a $35m Series D financing.
The round was led by Adage Capital Partners, LP., with participation from new investors Longwood Fund and two other institutional investor groups, as well as existing investors Morgenthaler Ventures, Advanced Technology Ventures and Delphi Ventures. In conjunction with this financing, Christoph Westphal, MD, PhD, Partner and Co-Founder of the Longwood Fund, will join Calithera’s Board of Directors as an observer.
The company intends to use the funds to accelerate the development of its clinical-stage candidate CB-839 through Phase 1 clinical trials in patients with advanced solid and hematological tumors, and to continue to develop its pipeline of novel therapeutics, including an inhibitor of MCL-1, an anti-apoptotic BCL-2 homolog over-expressed in many cancers.
Led by Susan Molineaux, PhD, President and Chief Executive Officer, Calithera Biosciences is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival. Its lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism.